SA
CPRX

Sanctuary Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Sanctuary Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Sell
94,996
-19,801
-17% -$472K 0.01% 877
2025
Q4 		$2.68M Buy
114,797
+55,636
+94% +$1.24M 0.01% 782
2025
Q3 		$1.17M Buy
59,161
+27,551
+87% +$567K 0.01% 1202
2025
Q2 		$686K Sell
31,610
-12,809
-29% -$302K ﹤0.01% 1424
2025
Q1 		$1.08M Sell
44,419
-15,028
-25% -$338K 0.01% 1095
2024
Q4 		$1.38M Buy
59,447
+28,407
+92% +$610K 0.01% 1066
2024
Q3 		$667K Buy
+31,040
New +$575K ﹤0.01% 1521

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Sanctuary Advisors's CPRX Position: Q1 2026 in Review

Sanctuary Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 17% in Q1 2026, selling an estimated $472K and leaving 94,996 shares worth $2.35M. The position accounts for 0.01% of the portfolio, ranked #877.

Sanctuary Advisors first reported a position in CPRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.68M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Sanctuary Advisors held 94,996 shares of Catalyst Pharmaceutical worth $2.35M as of Q1 2026.
  • Sanctuary Advisors sold 19,801 Catalyst Pharmaceutical shares in Q1 2026, an estimated $472K.
  • Catalyst Pharmaceutical made up 0.01% of Sanctuary Advisors's portfolio in Q1 2026, its #877 holding.
  • Sanctuary Advisors first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 7 quarters since.
  • Sanctuary Advisors's Catalyst Pharmaceutical position peaked at $2.68M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Sanctuary Advisors's 13F filing for Q1 2026, filed 5 May 2026.